Electric vehicle bubble deflates as valuations plunge – what’s next for the EV industry?

The electric vehicle (EV) industry, once riding high on optimism and sky-high valuations, has hit a roadblock as investors and car manufacturers reevaluate their strategies amidst a slowdown in growth. Factors ranging from rising interest rates to evolving EV technology and consumer preferences are being cited as reasons behind the shift in momentum.

Read More

Inflation eases, but RBA remains cautious

Inflationary pressures eased slightly in October, as many economists had forecast, following a poor result in September and data for the September quarter. However, the improvement is not a cause for great excitement and will not lead the Reserve Bank to change its stance on the risks of "sticky" inflation, heightened expectations, and potential interest rate hikes.

Read More

Chariot’s off to the races

Chariot Corporation (ASX:CC9) witnessed a remarkable 35% increase in its share price yesterday, closing at 70 cents with $700,000 in stock trading volume,. And the positive results have been continuing today, currently trading above 6% higher at 74.5c (2:00pm AEDT). While no new developments were reported today, the recent announcement of the arrival of a drill rig at CC9's flagship Black Mountain Project in Wyoming, USA, has been driving investor interest over the past two weeks.

Read More

Chimeric Therapeutics shows promise in ovarian and pancreatic cancers

Chimeric Therapeutics (ASX:CHM), an Australian company specialising in cell therapy, has reported significant in vitro findings for its chlorotoxin (CLTX) chimeric antigen receptor (CAR) NK cell therapy, CHM 1301. These preclinical results highlight the therapy's notable efficacy against ovarian and pancreatic cancers, suggesting potential advancements in cancer treatment.

Read More